1. Home
  2. NOVA National School of Public Health
  3. Master in Health Promotion
  4. Pharmacy Utilization Analysis in Portugal

Pharmacy Utilization Analysis in Portugal

Objectives

Learning outcomes of the curricular unit 

At the end the students will / should be able to:


Understand the interrelationships at different stages of the product cycle, to identify the role of different actors and understand the effect of policies on drug use;


Understand the role of various professionals in the use of medications, within a framework that ensures its effectiveness and patient safety, according to national and international guidelines;


Understand the financing system of medicines and management of the system of reference prices applied to the use of generic drugs;


Analyze the effective use of medicines in Portugal and outpatient hospital care;


Understand the tools of analysis for economic evaluation of medicines.

 

 

 

General characterization

Code

9513

Credits

4.0

Responsible teacher

Ana Maria Escoval

Hours

Weekly - Available soon

Total - 26

Teaching language

Português

Prerequisites

Requirements for frequency 

No requeriments.

Bibliography

Bibliography

APIFARMA - Política de acesso ao medicamento em Portugal. Lisboa: Apifarma, Janeiro 2013.

DELOITTE. APIFARMA – Relatório: Caracterização das falhas de abastecimento no mercado farmacêutico nacional: atualização 2013. Lisboa: Deloitte, 2013.

INFARMED - Relatório “Monitorização do Mercado de Medicamentos em Ambulatório”. Lisboa: Infarmed, Janeiro 2014.

OECD - Health at a glance 2012: OECD indicators. [Em linha]. Paris: OECD Publishing. Organization for Economic Co-Operation and Development, 2013. [Consult. 17.03.2014]. Disponível em http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf

THINK TANK INOVAR SAÚDE - Pensar a saúde: promover e disponibilizar a inovação aos cidadãos. Lisboa: Escola Nacional de Saúde Pública, Dezembro 2013.

Teaching method

Teaching methodologies (including evaluation)

Theoretical sessions;

Seminars (critical analysis and discussion of case studies);

Group work presentation and discussion.

Evaluation:

Punctuality and attendance (5%)

Participation (10%)

Individual test with 10 multiple choice questions (35%)

Group work (50%)

Evaluation method

 

Punctuality and attendance (5%)

Participation (10%)

Individual test with 10 multiple choice questions (35%)

Group work (50%)

Subject matter

Syllabus 

Sessions 1 and 2

  • Introduction to Curriculum Module
  • The cycle of medicament

 Sessions 3 and 4

  • Health Technologies evaluation  

 Sessions 5 and 6

§  Analysis of Access to Therapeutic Innovation

 Sessions 7 and 8

  • Drug policies analysis and health system organization

 Sessions 9 and 10

  • Pharmacovigilance and drug safety

  Sessions 11 and 12

  •  Evaluation

 Sessions 13 and 14

  • Seminar